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ABSTRACT
There has recently been a dramatic increase in demand for healthcare innovation. In this thesis
we present a framework for analyzing a digital health innovation ecosystem in the US. Our
framework consists of four key activities: innovation generation, entrepreneurial team
formation, early company incubation, and validation of the core innovation. Throughout the
paper we analyze the existing literature around innovation in order to motivate the design of
the framework.
The framework is applied to three key innovation ecosystems in the US; Silicon Valley, Boston,
and New York as a way to illustrate how this tool can be used to analyze digital health
ecosystems in order to understand what key areas exist for improvement. We end the thesis
with a discussion of the various programmatic ideas that might be used to bolster each
category as well as a discussion of adapting this type of ecosystem development to the natural
capacity of a region.
Thesis Supervisor: Fiona Murray
Title: Sarofim Family Career Development Professor of Management of Technological
Innovation & Entrepreneurship
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Introduction:
Over the past 5 years there has been a surge in healthcare innovation activity. In this paper
we present an overview of these activities to better understand the landscape of digital
health innovation in the US. Much of our analysis here may apply to other domains,
however, for the purposes of this paper we remain oriented to activities in the US related to
digital health. We focus specifically on innovation driven entrepreneurship. While,
innovation does happen in larger firms, it has been shown that most new innovative
products and technologies come from entrepreneurial firms (Schumpeter 1934, Tushman
& Anderson 1986, and Henderson & Clark 1990) and therefore we believe this focus is the
most productive way to understand the innovation ecosystem and the opportunities to
further encourage innovation.
In this paper we have three goals:
1. Understand what is currently happening in key digital health innovation ecosystems
in the US.
2. Understand the role that each of these organizations plays within the larger context
of digital health innovation.
3. Understand what opportunities exist to improve these ecosystems and accelerate
the pace of innovation in healthcare.
To achieve these goals we present a framework for understanding innovation driven
entrepreneurship in digital health. We then review a number of key innovation
organizations and how they relate to this framework both as a way to better understand
the framework as well as to understand the individual roles of each of these organizations.
Subsequently, we apply this framework to several key regional digital health innovation
ecosystems in order to understand if opportunities for improvement exist. Additionally,
we hope that in presenting this framework and analyzing several key ecosystems we can
empower members of those and other ecosystems with a new methodology to perform this
type of analysis in the future. We end the paper with a discussion of these results as well as
a discussion of a number of different programmatic options to enhance these ecosystems.
Background
Why should we care about digital health innovation ecosystems?
The last five years has seen a rapid growth in the type and number of organizations
supporting innovation in healthcare, both at the level of the Federal Government as well as
through a number of regional grass roots organizations. New Federal efforts to encourage
innovation and technology adoption include: the HITECH Act, which helped double rates of
EMR adoption (US Department of Health and Human Services 2013), The Medicare and
Medicaid Innovation, and the recent Open Data initiatives at The Department of Human and
Health. Outside of Washington DC we have seen an equally historic focus on supporting
healthcare innovation through the rapid growth of healthcare accelerators like Rock
Health, community organizations like Health 2.0, and new hospital innovation centers like
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the Garfield Center at Kaiser Permanente. As we continue to commit substantial resources
toward innovation in healthcare it is important to understand what role they play in the
ecosystem and what opportunities exist for improvement.
Why do we care about innovation in healthcare in the first place? The core challenge to
society is the rise in healthcare costs in the last several decades - far outpacing the growth
in GDP (Figure 4). In the US we spend more (as measured by either percent of GDP or per
capita) than virtually any other industrialized nation. Yet for all of these resources our
population level health outcomes are near the bottom of any industrialized country (Global
Health Expenditure Database 2013). Additionally, by some measures medical errors are the
leading cause of death in the US (Herzlinger 2006). Not surprisingly it was shown that the
pace of innovation in healthcare has been slow (Cutler 2011), thus many in the country are
looking to better understand how to support a more innovative healthcare environment as
a step to solving some of the larger questions about the effectiveness of our healthcare
system in the US. We hope that this paper can provide a framework for understanding what
is currently being done to encourage digital health innovation in the US as well as being a
framework to further enhance our current innovation ecosystems.
Framework for Understanding the Innovation Ecosystem
There are many models of innovation covered in the literature. We will not attempt to do
this literature justice here'. For the purposes of this paper it is important, simply to
reference several key ideas common in the literature. The first is that a simple linear model
of innovation in which all innovation is pushed onto society from science (ie science push
model of innovation) is not accurate (Martin & Tang 2007). Secondly, we assume in this
paper that some innovations are primarily inspired by new technological discoveries while
others are motivated primarily by a market demand. Third we assume that the vast
majority of innovations require input from the market throughout the various stages of the
innovation process.
Figure 1: Innovation Framework
Figure 1 above gives an overview of the framework we will use to analyze the various
actors in the innovation ecosystem. Our framework has four key activities:
1. Innovation (or "idea") generation
2. Entrepreneurial Team Formation
3. Early Company Building
1 If you are interested in reviewing several different systems of innovation, consider Martin
& Tang 2007.
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4. Early Validation (usually in the form of a pilot or test that establishes that the
product solves a critical problem and meets a key market need).
It is important to note that these activities do not happen in a strict linear order, in fact they
most likely follow a non-linear path. There are many models that describe this non-linear
process, two prominent ones are Spiral Innovation (described in a forthcoming paper from
the Center for Biomedical Engineering at John's Hopkins) and Design Thinking (Brown
2008). Broadly, the generation of new innovation and the formation of a team happen at
interchangeable moments. Sometimes the innovation (especially in a formal R&D setting)
precedes all other stages, however, frequently teams form to tackle a specific problem and
the innovation is discovered by that team as they begin to better understand the problem.
Similarly, while the validation and early company incubation generally happen after the
innovation generation and team formation these steps often feedback on each other. A
team may learn something during the testing and validation that causes them to repeat the
innovation generation or in some cases even reconfigure a team based on a new
understanding of the problem and the opportunity. The purpose of this framework is not to
advocate for a specific order of these activities but rather to suggest that these activities are
somewhat distinct and therefore this framework is a useful construct for understanding
how the different programs within an ecosystem support each of the activities in the
innovation lifecycle.
In addition to the iterative nature of innovation, its location is also important. There is a
substantial literature which shows that region / industry based clusters of activity predict
the level of entrepreneurial activity better than a solely region based or industry based
analysis (Delgado 2010). There are likely several reasons why location matters for
innovation. The clustering of firms (both entrepreneurial and established) around an
industry will attract specialty knowledge and resources to the region (Porter 2000).
Furthermore, some resources are specific to entrepreneurial firms such as risk capital and
legal resources (eg IP, company formation). Additionally, it is expensive to move
information and people across geographic boundaries (Ellison 2007, Audretsch 1998).
Even more important is the fact that information about innovation itself is especially
"sticky" (Von Hippel 1994). The farther apart those who understand the problem are from
those who understand the solution, the more resources it will take to communicate it,
which will slow or prevent innovation from happening. With this backdrop we will discuss
the nuances of each activity within the framework.
Idea / Innovation Generation:
Innovations can originate from a variety of contexts; however, these sources can generally
be grouped into one of two categories:
1. Formal R&D
2. Autonomous Innovations
Formal R&D:
Formal R&D includes:
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1. Commercial R&D Labs (ie Pfizer)
2. Research University Labs (ie MIT)
3. Hospital Innovation Centers (ie Mayo Clinic Center for Innovation)
Historically, it was believed that large research laboratories drove virtually all innovation.
Increasingly, we are beginning to understand that different forms of innovation come from
different places. Formal R&D certainly provides a strong foundation for many innovative
activities and it is the source of many innovations, but innovation is complex and it is
reductionist to simplify its sources to a single type of activity such as research in a
laboratory.
A newer form of formal R&D is the innovation centers at hospitals. Many of these were
founded within the last 10 years. Relative to most university based R&D labs, these centers
of innovation focus on applied research, in particular they are often places for clinicians to
explore new clinical protocols2 .
Autonomous Innovations:
An often-overlooked form of innovation is autonomous innovation. These are innovations
that originate outside of formal R&D environments. Some research has suggested that
these even makeup the vast majority of new products and services (Von Hippel 2005).
These innovations generally result from the intersection of problem rich and solution rich
environments. In the literature these people are referred to as "lead users" because they
are the people who directly experience the problem on a daily basis and thus understand
that problem best. In healthcare, these are likely to be clinicians or patients suffering from
a specific problem and motivated to find solutions to it. One of the challenges for this style
of innovation in healthcare is the fact that the people who understand the problem best
(clinicians) are also very unlikely to have the engineering skills to develop a new
technology-based solution 3.Therefore, these solutions will likely result from collaborations
with engineers and others that have an understanding of how to build these solutions. An
important element of the lead-user literature is the idea that the information required to
develop new innovations is "sticky" (Von Hippel 1994). Namely, with each link in a chain
that the information has to travel it requires an exponential increase in resources to
effectively transport that information to the new party. Thus we can expect that to
encourage this kind of autonomous innovations we need to encourage clinicians and
patients to interact with engineers in order to overcome this natural barrier in healthcare.
This further suggests that location matters and that these innovation ecosystems must be
regional in nature because they benefit from frequent interaction between these different
parties.
2 See http ://kpnet.kp.org/innovationcenter/what-we-do.html and
http://www.mayo.edu/center-for-innovation/what-we-do for a more detailed description
of the services and activities they provide (primarily to clinicians at these institutions).
3 For a review of medical school acceptances by undergraduate field of study see:
https:://www.aamc.org/download/321496/data/2012factstable18.pdf. As shown in that
chart, very few medical school entrants have an engineering background.
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Programs to Encourage Innovation Generation:
There are an infinite number of ways in which to encourage more innovation generation.
Traditional funding from government programs like the NIH for formal R&D laboratories
has been proven to be effective (Martin & Tang 2007). In addition to these traditional
activities it is also important to focus on programs that encourage autonomous innovation.
Several examples that exist in various ecosystems include conferences / meetups 4,
hackathons, and prizes.
Conferences and meetups provide a critical activity in educating engineers (ie solution rich
environments) to critical needs worth solving. A good example of these types of
conferences are the Pain Points in Healthcare meetup in Boston, as well as larger
conferences such as Health 2.0's Matchpoint Conference. Because location matters, it is
critical that these activities take place frequently and in all ecosystems; a conference in San
Francisco is unlikely to impact the autonomous innovation of Boston. Furthermore, it is
important that conferences be part of a larger ecosystem in order to have impact.
Hackathons are another example of an event type that encourages autonomous innovation.
A hackathon can have any number of formats, but a very common format is a weekend long
event in which a diverse audience of clinicians, engineers, entrepreneurs, and designers
collaborate to develop new ideas that they think would help to solve a need in the world.
While this format fills several different needs in the innovation ecosystem, one of those
needs is to generate new ideas (or innovations) - which is to be expected given the
theoretical framework about sticky information and lead-user innovation. A good example
of these events is the Hacking Medicine events in Boston (http://hackingmedicine.mit.edu).
A final program type that encourages both autonomous innovation as well as formal R&D
are prizes. Prizes, such as the XPrize Tricorder
(http://www.qualcommtricorderxprize.org/) can be very effective at focusing and driving
innovation toward a specific goal (Murray 2012).
As showcased above there are a number of ways to encourage innovation both in formal
R&D environments as well as in autonomous environments. We will see later how these
efforts fit into specific ecosystems throughout the country.
Team Formation:
A dynamic innovation ecosystem needs to have both innovation capacity and
entrepreneurial capacity. Regardless of the source of the actual innovation, most new
innovative products come from entrepreneurial entrants, and therefore require an
entrepreneurial team. In order for the innovations to have impact in the world a firm needs
to attract the necessary resources to create a viable innovation. We know that the ideal co-
founding teams have diverse backgrounds and some history working together (Wasserman
4A list of frequent meetups in Silicon Valley, Boston, or New York can be found by
searching for "digital health", "quantified self', "Health 2.0", etc.
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2012). This is a particular challenge in healthcare because it is also the case that large
hierarchical firms (exactly like the ones that dominate healthcare) are the least likely to
generate new entrepreneurial teams (Burton 2001). To overcome this challenge we need to
take extra steps in healthcare to encourage new diverse teams to form. This is a second,
and important, role that conferences and meetups play in the innovation process.
It is also where hackathons excel. One reason why they are likely to be more successful
than a standard meeting or conference is the fact that they time compress the experience of
working together as a team. This is no replacement for time - ultimately it takes longer to
identify if a team truly works well together, however, it can help to short circuit the process
by acting as a useful first filter to show teams what it might be like to work together.
Interdisciplinary classes are another good example of encouraging this type of team
formation. The audience for these is limited (as they only take place at Universities to our
knowledge) however they have the same general effect as hackathons in that they
encourage diversely skilled student teams to form around an idea for the length of a
semester. A number of universities have good examples of these programs however one of
the best is Biodesign at Stanford. It was originally focused on medical devices but has
recently expanded its focus to include healthcare.
The ideal entrepreneurial team has a good culture fit that is hard to predict ahead of time in
addition to the right set of skills and knowledge necessary to turn the core innovation into
a new product or service while simultaneously building a new company to take the product
or service to market, therefore the best ecosystems are those that have a number of
different networking events, workshops (ie hackathons) and other activities (such as
classes) to encourage diverse teams of potential entrepreneurs to work together as a test of
whether they would make a good long term entrepreneurial team. This is at the core of why
ecosystems with porous boundaries frequently perform best at generating new
innovations.
Early Company Incubation:
There is a period directly after the entrepreneurial team has formed when the firm knows
approximately the innovation it wants to create and it now needs time to build the
company. This requires validating that the core idea can be built - ie turned from a
technology into a product. It requires validating that the market has a need that is solved
by this innovation in a manner that potential customers are willing to pay for. It also
requires a number of logistical yet important steps such as incorporating, protecting IP,
raising seed capital, and recruiting additional team members. Informal networks support
all these. Networking events, open office hours from serial entrepreneurs, and community
organizations (ie Health 2.0) support this process, which is yet another reason why these
are important elements of an ecosystem. Accelerators are the most direct type of support
for this activity. There has been a recent surge of new healthcare accelerators in the last
five years driven initially by Rock Health. For a great review of these and other accelerators
see: httpjjwww.chcf.org/publications/2013102 seeding-digital-health.
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These accelerators focus on providing new firms access key mentorship resources that
each of the elements of company development above. These organizations play a
particularly key role in healthcare because they can help provide new teams with key
skillsets through mentors and new team members that they would not otherwise have. As
we've already noted in this paper the structure of current healthcare firms does not
support or encourage the ideal team makeup and therefore it stands to reason that these
accelerators can help serve a critical role by helping to support an early team that might be
missing a particular skill or expertise. It should be noted however, that through their
acceleration activities these organizations do not specifically encourage team formation or
makeup for teams lacking a core skillset. In fact, most of these accelerators use team
makeup as a core element of whether to accept a team into their accelerator so these are
not a replacement for encouraging the right kind of team. However, they can be a useful
support structure for a team that has most but not all of the skills and expertise necessary
to be successful. Another important element of accelerators is to help entrepreneurs
connect with industry partners. This can be the foundation of new pilot projects. In the next
section we will discuss the need for testing and validation of new innovations and the
unique challenges in digital health.
Testing and Validating a New Innovation:
As an innovation is developed and brought to scale, it must be tested and validated. For a
new firm they frequently need to validate the market - validate that there is a customer
willing to pay for what they are building. Market validation can be done with largely the
same methods as with any innovation - through market research (surveys, customer
interviews, letter of intent to pilot once it is built, etc). In addition to market validation, a
young firm must also validate the clinical value of the innovation5 . Generally, this process
happens through a formal research pilot (similar to a clinical trial for a drug or device) or
through an ad-hoc pilot with a specific physician or group of physicians. Formal research
pilots can take months (or years) to setup and require a substantial amount of buy-in from
everyone in the clinical organization. This process can easily take 6 months to a year. Many
innovations simply find a physician who is excited to help pilot the given innovation with a
group of willing patients. This latter approach, while often faster and more flexible relies on
the personal and professional networks of the entrepreneurs involved, and subsequently
limit the likelihood of autonomous innovations.
While any medical innovation can likely be approached (and should be) in an iterative
fashion, digital health presents a unique opportunity to approach innovation in an
especially iterative fashion. This is due to the fact that the product development life cycle of
software is very short and iterative. It is also the result of the fact that the original core
s It should be noted that some digital health innovations are focused on providing backend
tools for healthcare organizations, either as tools for the organizations (such as EMRs) or as
tools for individual physicians (such as applications to help physicians text each other). We
are focused here on describing the validation process for digital health innovations that are
focused on meeting a clinical need.
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innovation and the resulting product are more decoupled than they might be in drug
development.
To better understand several of the unique components of testing and validating digital
health innovation, consider The Diabetes Prevention Program (DPP) (Orchard 2005). The
DPP is a lifestyle intervention that slows the progression of Type II Diabetes. Omada Health
(http://omadahealth.com/), a startup in San Francisco, is trying to bring this innovation to
scale by delivering the intervention through a web and mobile experience. The original
innovation was the actual design of the lifestyle intervention. It is reasonable to expect that
the intervention will have the same effect through a website as through paper based
interventions. However, because the delivery mechanism is different it needs to be re-
validated, though it is less a question of whether it will work and more a question of exactly
how to construct the software to achieve the original results. Thus it is critical to enable a
validation environment that matches this iterative process.
In drug development this does not happen because the core compound does not changed.
Once the drug itself has been developed it is then validated. The development of the
software itself is so flexible that it enables a test and iterate cycle that is not possible with
drug development. In an ideal development environment, the process of validating this
innovation would be iterative. For example, a group of users who have volunteered to help
test a product would be able to rapidly give feedback on each new iteration of the product
(which might be as often as daily or weekly). This iterative process would continue until
the product began to show the clinical impact expected by the original core innovation.
There are very few formal organizations or programs to reduce the barriers to an
entrepreneurial firm finding a pilot site. Generally these include:
1. Networking events: as mentioned earlier these help build informal networks, and
thus they can be a source of encouraging more pilots to happen.
2. Accelerators: attempt to connect their participant entrepreneurs with the right
people at healthcare organizations who can help them establish a pilot at their
organization. In particular the New York eHealth Accelerator actually accepts
companies with the guarantee of a pilot.
Summary
We have presented a framework here for understanding the key activities that the different
organizations in the digital health ecosystem support. Those activities include the
generation of new innovations, the formation of a team around those innovations that can
drive them forward as new firms, support them, and incubate them, as well as help with the
process of validating these new innovations as they attempt to reach scale.
Data Collection and Methods:
In order to collect data about the state of each of these ecosystems we did a cursory review
of a larger number of ecosystems (shown in Figure 2 below), before doing a deeper
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analysis of our three core ecosystems. We collected data by searching the web for
innovation organizations and programs by location as well as visiting frequent organizing
sites like meetup.com. Finally, we interviewed a number of entrepreneurial experts in each
ecosystem in order to double check that we discovered the majority of organizations
driving the innovation ecosystems. It is impossible to know if we have captured every
single group and organization supporting innovation, however, our primary goal is to get a
sense of the types of activities happening in each ecosystem and therefore our analysis
does not rely on capturing 100% of the activities that are ongoing in each location.
In addition to researching the activities in each ecosystem we wanted to assess the inputs
and outputs of each ecosystem as well. Therefore, we captured the "entrepreneurial
capacity" of each region in a 1 - 5 score representing the degree to which our interviews
uncovered a cultural bias for innovation as well as the degree to which we found specific
organizations supporting every stage of the innovation framework presented in this paper.
We then specifically assessed the formal R&D capacity of each region by totaling the
amount of NIH funding in each region, the total VC funding in each region (not only digital
health), the number of early stage digital health investment deals, and the number of
meetups on meetup.com that pertain to healthcare innovation.
We assess the NIH funding using the online tool to download all funding data from the NIH
by institution and city (see http://report.nih.gov/award/index.cfm). We then grouped the
cities according to each ecosystem's region and summed up the total funding. We used a
Price Waterhouse Coopers report to assess the total VC funding in each ecosystem in 2012
(see https://www.pwcmoneytree.com/MTPublic/ns/index.jsp). The number of digital
health investment deals was computed in an investment report from Rock Health (see
http://www.slideshare.net/RockHealth/2012-year-end-funding-report). Finally we
computed the number of meetups by searching that site's repository of activities. The
results are presented in the table below:
$1/770.846,123 I $3,296,474,700 20 4
Silicon Valley 5 $1,264,047,030 $10,968,046,700 27 9
Baltimore 1 $1,254,961,675 $735,402,000 2 3
Seattle 2 $868,378,028 $1,052,501,000 51
NYC 4 $823,040,093 $2,360,490,700 2 15
7
Chicago 3 $710,112,866 $1,391,918,800 7 2
Cleveland 2 $303,296,477 $285,750,500 2 0
Figure 2: Quick overview of key metrics for various ecosystems
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Additionally, the following table presents an overview of the organizations that we
investigated and considered as part of this process across each of the ecosystems that we
reviewed.
Stage
Team Initial Test/
Innovation Generation Formation Incubation Validate
Region /Organization Formal R&D Autonomous
Boston
Center for Connected
Health @MGH X_ X
Stoeckle Center @ MGH X
CIMIT @MGH X X X
Innovation Fund 0 Boston
ChiIdrAn~ X
Hacking Medicine X X
Rock Health X
Healthbox x
Oreilly's Health Foo X X
Strata Rx X X
Health 2.0 Conferences X X
Garfield Center @ Kaiser X
Biodesign X X
Rock Health x
StartX Med X X
Oreilly's Health Foo X X
Health 2.0 Conferences X X
Strata Rx X X
Health Hatch
(https://www.healthtechhat
ch.com/) X
Prebacked
(http://www.prebacked.co
m/ignition/bcbs#schedule) X
TEDMED X X
Center for Bionengineering
Innovation and Design X X X
r--i-d-e-s-
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MacColl Center for
Healthcare Innovation X
NYC
NY Digital Health
Accelerator X X
Blueprint X
Wired Health Conference X X
Strata Rx X X
Chicago
NUvention X X
Healthbox X
Health 2.0 Conferences X X
Cleveland
Cleveland Clinic
Innovation Alliance X X X X
Minnesota
Mayo Clinic Innovation
Center X
All Regions
Data Design Diabetes
Competition X X
XPrize Tricorder X X
Health 2.0 Dev Challenges X X
Startup Health X
Key Regions of Innovation
In order to get an overview of the relationship between innovation capacity in each region
and level of entrepreneurial activity, we charted the level of NIH funding in each region
against the entrepreneurial capacity of that region. This can be seen below:
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Formal R&D Spend (2012) and Eship Capacity
* Boston
4 Baltimore
.2
0 Silcon Valley
$2.000
$1,800
$1.600
$1,400
$1,200
$1.000
$800
$600
$400
$200
0 Chicago
Cleveland
2 3
Entrepreneurship Capacity
4 5
Figure 3: Formal R&D spending measured by NIH funding, and entrepreneurial capacity as measured by evidence
of entrepreneurial ecosystem.
We then did a deeper analysis using our framework and the data presented above of three
key innovation ecosystems: Boston, SF / Silicon Valley, and New York City.
We chose Boston because it is one of the major innovation ecosystems, independent of
industry, and because it is particularly known for healthcare innovation driven both by its
innovative policy environment and the number of research universities per capita. San
Francisco and the Silicon Valley innovation ecosystem is still the premier ecosystem in the
world and thus it is critical for us to analyze it through the lens we have been developing in
this paper. We chose New York as our third ecosystem because the New York eHealth
Collaborative and its associated Digital Accelerator are very unique features that we have
not seen replicated elsewhere.
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Ecosystem #1: Boston
Boston is arguably the best innovation ecosystem for healthcare in the world. Certainly, at
the level formal R&D activity it is home to a number of the world's top research universities
and it is consistently the largest recipient as a region of NIH funding (Weisman 2013).
Probably the single weakest point regarding Boston (especially compared to Silicon Valley)
is its culture (Saxenian 1996). It is home to a great entrepreneurial culture, however, that
culture is not as open and collaborative as its counter part in Silicon Valley. This was one of
Saxenian's key findings and we also noticed it in interviews of the two ecosystems.
There are a couple of groups in Boston that specifically try to encourage autonomous
innovation as well as diverse team formation. These are, however, areas that are ripe for
more activity. Especially given the level formal R&D activity our framework suggests that
substantially more innovation would be generated and scaled by focusing on encouraging
autonomous innovation and team formation. It is also important to note that there is a very
active Venture Capital and Angel Investing community in the Boston area. This makes it
easier to get seed funding than in other ecosystems. It also can be a source of team
formation as VCs act as the center of networks. Several of the teams that we interviewed
for this paper mentioned finding key talent through local Venture Capitalists.
Boston has great support for early company incubation. It has two accelerators focused on
healthcare and a third very high quality accelerator that has mentored healthcare
companies in the past. It has two formal entities that support early stage validation of
innovations and startups; CIMIT and Center for Connected Health. Support for pilot
projects would greatly benefit from an enhanced culture that was more encouraging of
experimentation and openness. We did not find the same reception when interviewing
members of the healthcare community in Boston as in San Francisco. Additionally, Rock
Health was conceived of in Boston (at Harvard Business School) yet it was founded in San
Francisco because they could not find receptive partners in the Boston medical community
to collaborate with.
Ecosystem #2: San Francisco / Silicon Valley
In this paper we treat San Francisco and the Silicon Valley as a single ecosystem. As one
ecosystem it is the most dynamic engine of innovation in the world. While it does have a
wealth of programs for supporting entrepreneurship and innovation, as we will see in a
moment it is not clear that it has more than the Boston community. However, what it does
have is an advantage on culture. Its culture supports an openness that supports grass roots
level cross-pollination. While this impacts a number of different areas across the
innovation ecosystem, it particularly impacts autonomous innovation as well as validating
new ideas.
Several programs that the Silicon Valley ecosystem has that are unique are the StartX Med
community and the Biodesign program. The biodesign program is primarily focused on
medical devices, however, recently it expanded its focus to encompass digital health. The
program is particularly good at encouraging diverse groups of people to collaborate on new
innovations. StartX Med is an accelerator run by a young group of Stanford students
(though it is a separate non-profit). It is notable because it has encouraged collaboration
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and innovation between the Stanford Hospital and innovators who need help establishing a
pilot project or an opportunity to test and validate.
Ecosystem #3: New York City
New York City has been making a serious commitment to innovation generally in recent
years. With the introduction of General Assembly, the Mayor's initiative to bring in an
applied sciences technology campus, and the New York eHealth Collaborative, there are a
number of new programs and efforts to encourage autonomous innovation and team
formation. However, many of these efforts are not specifically focused on healthcare. As can
be seen in the chart below, there is significantly less support for generating innovation as
well as for team formation.
Notably, however, New York's eHealth Collaborative recently established a Digital Health
Accelerator. This accelerator gives portfolio companies up to $300,000 and a guaranteed
clinical pilot partner to help validate the idea. This is the first example of an accelerator
(that we know of) taking an explicit role in ensuring seed stage funding, early company
mentorship, as well as an environment to validate against. The primary challenge for New
York is culture. They don't have a culture of innovation. This is beginning to change outside
of healthcare through organizations like General Assembly. We found significant cultural
challenges, however, in the interviews we did relating to the academic medical centers.
There was a significant stigma about participating in commercial activities. This resulted in
hesitation about spinning companies out of academic centers of innovation as well as for
participating in the early stage validation or development of a company.
Discussion:
One overarching theme is the degree to which an ecosystem as innovation capacity versus
entrepreneurial capacity. As seen in Figure 3, some ecosystems have substantial innovation
capacity, however they lack the entrepreneurial activities necessary to encourage the rest
of the innovation life cycle in our framework. These ecosystems could likely extract
substantial value by focusing on adding events and activities that support team formation,
company incubation, and validation support. A good example of this is actually Cleveland
Clinic. The innovation center is one of the few organizations in the country that focuses on
this entire life cycle. More needs to be done in Cleveland, but the innovation center is a
significant step toward adding entrepreneurial capacity.
For some ecosystems, the challenge is creating innovation capacity. This is often
particularly daunting for policy makers because they naturally default to assuming that
they must build a world-class research institute in order to increase their innovation
capacity. This is certainly an admirable aim - and likely worth the investment - however, it
is not required. As we have seen in Boulder, CO, a dynamic innovation ecosystem can be
built without significant participation from the local university. As described in our
framework, ecosystems that need to generate more innovation capacity should focus on
autonomous innovation (mixing problem rich and solution rich environments) as a method
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for generating more innovation. This does not require significant public resources to
achieve.
Another critical element that most ecosystems overlook is culture. As we saw above Silicon
Valley is not (as measured by the number of programs) the obvious center of innovation
and entrepreneurship - however it clearly is. There is a long background literature
establishing the importance of culture in encouraging innovation. The key elements of an
entrepreneurial culture include encouraging openness to new ideas and a high tolerance of
failure. This is a culture that is often at odds with the other needs and requirements of
healthcare. For example, it has been shown that different companies generate radically
different rates of entrepreneurial activity (Burton 2001). One of the key reasons for this
appears to be the culture of an organization. Hierarchical organizations in which the roles
within the firm specialized and routinized (a description of most American hospitals)
exhibit lower rates of entrepreneurial activity. In fact the nature of delivering reliable high
quality medicine relies on this specialized and routinized culture (Gawande 2010, Gawande
2012).
Culture is one of the areas that we found most frequently overlooked when reviewing
innovation ecosystems. When discussing medical innovation with one interviewee when
discussing innovation at Mayo Clinic:
"You know the classic saying, if you have an innovation policy you aren't innovative. While
there are a number of [important] structure programs to encourage innovation, the most
important thing they [Mayo Clinic] do is to encourage a culture of innovation. They
encourage individual physicians to participate in startups and test and prototype new
ideas."
One example, we found of an organization encouraging an innovative culture was at
Partners Healthcare in Boston (though there may be many more). They supported new
innovation projects through an internal competition and fellowship, which empowered IT
staff to commit a portion of their time to a specific project of their choosing for a year. We
also observed an internal program at Aetna in which employees can apply for internal
funding for project ideas. If awarded they are allowed to spin the project out as a separate
company.
Culture is also very important in inspiring testing / validation because it encourages
physicians to innovate without permission. When open innovation and risk are
encouraged, it encourages clinicians at a grass roots level to collaborate with engineers and
technologists. One impact of this as described above can be the innovation itself, however,
in many cases it can also lead to the development of informal networks which lead to new
ad-hoc pilots and opportunities to validate a new idea.
Better support for the pilot process is a key opportunity, especially for clinical
organizations. One idea for doing this includes encouraging a culture among physicians
that towards experimentation. For example, Google employees are allowed to spend 20%
of their time on side projects. These frequently become the basis of new innovations such
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as Gmail and Google News (Mediratta and Bick 2007). This could be done in medicine by
encouraging physicians to spend 20% of their time developing new innovations of their
own or piloting new innovations from others. Additionally, they could devote some of the
innovation center resources to validating innovations as opposed to exclusively focusing on
new innovations. In this process the healthcare ecosystem needs to acknowledge the
iterative nature of software development and adapt its piloting processes (which were
designed with drugs and devices in mind) to the process of piloting digital innovations.
As Brad Feld points out in Startup Communities, building an innovation ecosystem has to be
lead by the innovators (in his terms that's the entrepreneurs) themselves. They have to
make a 20-year commitment. One of the first steps is to encourage these leaders in your
community to take a leading role. Part of engaging these leaders is that they can be key
connectors which can lead to connecting younger innovators who might form the basis of
autonomous innovations as well as help to accelerate the testing / validation steps, and
they can also support the early company incubation through angel financing and more
importantly mentorship.
Larger firms (hospitals, insurance providers, pharmaceuticals, device manufacturers, etc)
can play a key role in the community. They can help to create more porous boundaries
within their organization as well as to reward risk taking and even failure. These steps help
to encourage an innovation culture. They also can be the basis of further encouraging
autonomous innovation, supporting firm incubation, and more rapidly validating new
ideas. There are many benefits of moving to an open innovation culture for established
firms (include citation), while we wont repeat them all here, several key ones include
accelerating learning within the established firm by exposing it to outside experts,
enhancing existing regional clusters which can have a net benefit for the established firm,
and giving that firm the capacity to test new ideas through alternative startup vehicles
which can be acquired if an idea turns out to work. Similarly, the government can enhance
the innovation process by encouraging and funding innovation, and celebrating its
successes. In particular, policies which focus on reducing the barriers to testing and
validating new ideas will encourage more rapid digital health innovation. Culture is the
area that is most commonly overlooked in our experience. This may be because policy
makers feel it is something that they cannot affect. As we have seen above, there are
programmatic activities that can be encouraged which celebrate certain cultural ideals of
experimentation and openness that can be critical to pushing an ecosystem's culture in the
right direction.
Conclusion
In this paper we have presented a framework for understanding the digital health
innovation ecosystem as well as a methodology for analyzing a given ecosystem to look for
opportunities for improvement. Innovation ecosystems can be constructed in a variety of
ways and should not be dependent on a singular model of innovation (such as a science
push model). More research needs to be done to validate the specific values of the different
elements of our framework. While motivated by empirical evidence from the literature,
future research should seek to validate specific program activities and the degree to which
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they support each stage of the process. Finally, community leaders, policy makers, and
large firms can help to drive these innovative ecosystems by collaborating on programs
that encourage each stage of the innovation lifecycle as well as by focusing on the culture of
a region in order to encourage it to be more porous, more focused on experimentation and
taking risk, and ultimately more supportive of innovation.
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Figure 1: healthcare costs going up
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